Skip to main content
LQDA
NASDAQ Life Sciences

Officer Michael Kaseta Files Intent to Sell Over $5 Million in Liquidia Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$40.32
Mkt Cap
$3.553B
52W Low
$11.26
52W High
$46.67
52W Position info
258% above low
Off High info
14% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $11.26.

Summary

An officer at Liquidia Corp has filed a Form 144 to sell approximately $5.1 million in common stock, a notable transaction amidst the company's ongoing legal challenges.


Key Events · Ownership and Investor Activity · LQDA

  • Officer Files Intent to Sell Shares

    Michael Kaseta, an officer, filed a Form 144 to sell 133,789 shares of common stock, valued at approximately $5.1 million.

  • Significant Insider Distribution

    This proposed sale represents about 0.14% of the company's market capitalization and contributes to a pattern of over $6 million in net insider sales over the past 90 days.

  • Context of Legal Challenges

    The intent to sell occurs as Liquidia Corp faces critical patent and trade secret litigations that could impact its market access.


Analysis · LQDA · Life Sciences

Michael Kaseta, an officer at Liquidia Corp, has filed a Form 144 indicating an intent to sell approximately $5.1 million worth of common stock. This significant proposed sale, representing about 0.14% of the company's market capitalization, comes amidst ongoing critical patent and trade secret litigations that pose a threat to the company's market access. While the filing notes the shares were acquired through the exercise of stock options, the intent to sell such a substantial amount by an officer could be interpreted negatively by investors, especially given the company's legal challenges. This follows a pattern of insider distribution, with over $6 million in net sales by insiders in the last 90 days.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $40.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $11.26 to $46.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $43.10 info
Change: +$3.60 (+9%) info
Market Cap: $3.982B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $43.10 info
Change: +$11.34 (+36%) info
Market Cap: $3.982B info
LQDA
Oct 02, 2026, 11:47 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $27.77
Real-time Price: $43.10 info
Change: +$15.33 (+55%) info
Market Cap: $3.982B info
LQDA
Oct 01, 2026, 12:03 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $26.22
Real-time Price: $43.10 info
Change: +$16.88 (+64%) info
Market Cap: $3.982B info
LQDA
Sep 30, 2026, 1:20 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $53.22
Real-time Price: $43.10 info
Change: -$10.12 (-19%) info
Market Cap: $3.982B info